Weekly Report on Greater Health Industry: Quxel Bio Raises HK$100 Million via H-Share Placement; Sinocare Pharma Lists on HKEX

Quanxin Biotech Raises Approximately HKD 100 Million through General Mandate Placement of New H Shares

Quanxin Biologics (2509.HK) announced that it plans to place 5 million new H shares at a placement price of HK$20 per share, raising HK$100 million, with net proceeds amounting to HK$99 million. Approximately 60% will be used to repay existing interest-bearing bank loans; around 30% for the development of new pipelines; and about 10% as working capital and for other corporate purposes. The placement price represents a discount of approximately 10.95% compared to the closing price of HK$22.46 last Friday. The placement shares account for approximately 2.2% of the enlarged share capital. (Source: Financial World)

Yinuo Pharmaceuticals Listed on the Hong Kong Stock Exchange

On August 15, Guangzhou Yino Pharmaceutical Group Co., Ltd. (Stock Code: HK.02591) officially listed on the Hong Kong Stock Exchange, with an issue price of HK$18.68 per share. As a biotechnology company focused on innovative therapies for diabetes and other metabolic diseases, Yino Pharmaceutical has rapidly risen in the field of metabolic disease treatment since its establishment in 2014, relying on strong R&D capabilities, a rich product pipeline, and global layout. (Source: Arterial Network)

BioMap and Jinxi Technology Reach Strategic Cooperation

Recently, BioMap, the global pioneer in foundational large models for life sciences, and Jinxin Technology, the leader in China's assisted reproductive services, officially announced a strategic partnership. Leveraging their respective strengths and complementary resources, the two parties will jointly develop an AI-powered assisted reproduction system — the world’s leading intelligent platform for assisted reproduction. Through the deep integration of AI technology, they aim to enhance process efficiency standardization, data-driven industry decision-making, cycle trend optimization, and the upgrading of medical team training systems in reproductive healthcare. Together, they will also explore cutting-edge fields, ultimately optimizing IVF-assisted reproduction procedures and improving service experiences. (Source: Arterial Network)

Ab&B Bio-Tech's Key Product Receives Dual Approval in China and the US

On August 15, 2025, Ab&B Bio-Tech Co., Ltd. ("Ab&B Bio-Tech") and its subsidiary YiHui Biotechnology (Shanghai) Co., Ltd. ("YiHui Biotech") jointly submitted an IND application for a Class 1 new drug, "Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvant)," which was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration. (Source: Arterial Network)

Pleryon Completes Tens of Millions in Series A Financing

Pleryon, a biotechnology company focused on addressing unmet clinical needs with innovative polymers, announced today the completion of the first closing of its Series A round of financing worth tens of millions of RMB. This round of financing was led by EF Capital, a leading life science investment firm, with Haoyue Capital serving as the exclusive financial advisor for this transaction. (Source: VCBeat)

Pleryon Completes Tens of Millions in Series A Financing

Pleryon, a biotechnology company focused on addressing unmet clinical needs with innovative polymers, announced today the initial closing of its Series A financing round worth tens of millions of RMB. This round was led by Edge Capital, a leading life sciences investment firm, with Haoyue Capital serving as the exclusive financial advisor for the transaction. (Source: Arterial Network)

Rayvision Technology Secures Tens of Millions in New Round of Financing

Ruisi Technology Announces Completion of Tens of Millions in New Round of Financing; Two Months After June Fundraising, Company Receives Further Capital Support — This Round Led by Huaxi Jinzhi's Chengdu Huaxi Jinzhi Specialized and Innovative Equity Investment Partnership (Limited Partnership) ("Specialized and Innovative Fund"), with Existing Shareholder Innovation Works Increasing Investment; WinX Capital Served as Exclusive Financial Advisor. Funds Will Be Used for Clinical Registration, Sales Strengthening, Brand Building, Ongoing R&D Investment, and More. (Source: Arterial Network)

ZhiTong Technology Completes Tens of Millions of Yuan in Financing

Recently, Jiaxing Zhitong Technology Co., Ltd. (hereinafter referred to as "Zhitong Technology") announced the completion of a multi-million yuan A+ round of financing. This round of financing was exclusively invested by Hetang Ventures, with WinCapital serving as the exclusive financial advisor for consecutive rounds. The funds from this round of financing will mainly be used for the domestic and overseas registration applications and market promotion of the full range of surgical and ophthalmic surgical microscopes. (Source: Arterial Network)